Jove
Visualize
Contact Us

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

329
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
329
Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Actuarial Approach01:20

Actuarial Approach

63
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
63
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Trends In Breast Cancer-specific Death By Clinical Stage At Diagnoses Between 2000 And 2017.
  1. Home
  3. Trends In Breast Cancer-specific Death By Clinical Stage At Diagnoses Between 2000 And 2017.

Related Experiment Video

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017.

Michal Marczyk1,2, Adriana Kahn2, Andrea Silber2

  • 1Department of Data Science and Engineering, Silesian University of Technology, Gliwice, Poland.

Journal of the National Cancer Institute
|September 30, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Early-stage breast cancers (Stage I and II) now cause over 60% of breast cancer deaths, despite good prognoses. New strategies are needed to identify and treat early-stage patients at risk of recurrence to further reduce breast cancer mortality.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

223
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

116

Related Experiment Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

223
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:49

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

116

Area of Science:

  • Oncology
  • Cancer Research
  • Public Health

Background:

  • Metastatic breast cancer results in approximately 40,000 deaths annually.
  • Understanding the contribution of different disease stages to breast cancer mortality is crucial for public health strategies.

Purpose of the Study:

  • To determine the proportion of annual breast cancer-specific deaths attributed to Stage I, II, III, and IV disease.
  • To analyze temporal trends in these proportions over time.

Main Methods:

  • Utilized data from the Surveillance, Epidemiology, and End Results (SEER) Program (1975-2017).
  • Included 972,763 patients meeting specific criteria (female, single primary tumor, surgery, AJCC 6th edition stage > 0, no bilateral cancer, survival data).
  • Assessed temporal trends using linear models and ANOVA tests.

Main Results:

  • Between 2000-2017, the contribution of Stage I and II cancers to breast cancer deaths increased significantly (16.2% to 23.1% and 30.7% to 39.5%, respectively).
  • The contribution of Stage III and IV cancers decreased during the same period (36.4% to 30.3% and 16.7% to 7.1%, respectively).
  • Deaths from node-negative T1a, T1b, and T1c cancers also increased significantly, with similar trends observed for hormone receptor-positive and -negative cancers.

Conclusions:

  • Despite excellent prognoses, Stage I and II breast cancers now account for over 60% of breast cancer-specific deaths due to their high incidence.
  • Effective strategies are required to identify and treat Stage I and II patients at risk of recurrence to further decrease breast cancer mortality.